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Abstract
The protein kinase C (PKC) family of serine/threonine protein kinases share structural homology, while
exhibiting substantial functional diversity. PKC isoforms are ubiquitously expressed in tissues which makes it
difﬁcult to deﬁne roles for individual isoforms, with complexity compounded by the ﬁnding that PKC isoforms
can co-operate with or antagonize other PKC family members. A number of studies suggest the involvement
of PKC familymembers in regulating leukaemic cell survival and proliferation. Chronic lymphocytic leukaemia
(CLL), the most common leukaemia in the Western world, exhibits dysregulated expression of PKC isoforms,
with recent reports indicating that PKCβ and δ play a critical role in B-cell development, due to their ability
to link the B-cell receptor (BCR) with downstream signalling pathways. Given the prognostic signiﬁcance
of the BCR in CLL, inhibition of these BCR/PKC-mediated signalling pathways is of therapeutic relevance.
The present review discusses the emerging role of PKC isoforms in the pathophysiology of CLL and assesses
approaches that have been undertaken to modulate PKC activity.
Introduction
The protein kinase C (PKC) family of serine/threonine
protein kinases regulate numerous cellular processes in-
cluding survival, proliferation, differentiation, apoptosis and
migration. Members of this family are composed of N-
terminal regulatory and C-terminal catalytic domains that
are structurally closely related, but can be further divided
into three sub-classes based on their structural properties
and co-factor requirements: conventional, novel and atypical
PKCs (aPKCs). To date, ten distinct PKC isoforms have
been identified, encoded by nine genes [1,2]. Conventional
PKCs [cPKCs; α, β (alternatively spliced into βI and
βII) and γ ] contain diacylglycerol (DAG)-binding domains
(C1A and C1B) and a calcium (Ca2+ ) binding domain (C2)
in the regulatory region and require DAG and Ca2+ for
activation. Novel PKCs (nPKCs; δ, ε, θ and η) require DAG
and phosphatidylserine for activation, but contain a variant
of the C2 domain, which is unable to bind Ca2+ , rendering
nPKCsCa2+ independent. aPKCs (ζ and ι (λ in rodents) lack
functional binding sites for DAG and Ca2+ [3].
Maturation and activation of PKCs require phosphoryla-
tion events at AGC kinase conserved sites [2]. In the case
of cPKCs, the nascent protein associates with the plasma
membrane where it is phosphorylated at the activation
loop by phosphoinositide-dependent kinase-1 (PDK1). This
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event leads to further phosphorylation on the turn and
hydrophobic motifs of the PKC, which serve to stabilize
the protein, resulting in the release of the mature, primed
but inactive, PKC into the cytoplasm [1]. Agonist-induced
signals that result in hydrolysis of phosphatidylinositol-
4,5-bisphosphate lead to the generation of the second
messengersCa2+ andDAG,which enable PKC translocation
to the membrane. Engagement of PKC with the membrane
leads to a conformational change and full activation of
PKC, enabling the activation of PKC-mediated downstream
signalling events. The affinity of PKC for the plasma
membrane is dependent on the levels of available co-factors,
and the maintenance of phosphorylation. Indeed, PKCs are
sensitive to dephosphorylation by protein phosphatases such
as PHLPP and PP2A, which has an impact on their stability
[4]. In addition to translocating to the plasma membrane,
PKCs can also translocate to discrete subcellular locations,
binding to distinct receptors for activated C-kinase (RACK)
proteins, such as the keratin cytoskeleton, tight junctions,
Golgi apparatus and the endoplasmic reticulum [5]. Therefore
selected translocation of the activated PKCs to specific
cellular compartments can assist in the determination of cell
fate decisions.
PKC isoforms are ubiquitously expressed in tissues, with
studies demonstrating that PKCα, βI & II, δ, ε and ζ are
expressed in all major tissues, whereas PKCγ expression
is restricted to the central nervous system and spinal cord,
PKCη in the skin, lung, spleen and brain, PKCθ in the
skeletal muscle, lung, spleen, skin and brain [6–8]. These
expression profiles make it difficult to define roles for
individual isoforms, with the complexity compounded by the
finding that PKC isoforms can co-operate with or antagonize
otherPKCfamilymembers [9,10].Althoughgenetic targeting
of selective PKC isoforms has highlighted a degree of
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redundancy in the role of PKCs in normal cellular function,
this approach has demonstrated the unique role played
by individual PKC isoforms in specific cell functions. For
example, PKCα has recently been shown to play a critical role
in the interleukin (IL)-17A transcription in the Th17 helper
T-cell subset, through the regulation of transforming growth
factor β receptor 1 (TGFβR1)-mediated phosphorylation of
SMAD2-3 [11], whereas the PKCβ-knockout mouse model
revealed an immunodeficient phenotype with a pronounced
block in B-cell development, reduced numbers of B1 cells and
impaired antibody responses [12].
These studies highlight the complexity of PKC isoform
regulation at the level of the expression profile within
tissues/cells, differential regulation by co-factors and kinases
and the distinct expression pattern of RACKs that has an
impact on subcellular targeting. Each of these events is highly
regulated to generate a signalling response that is unique to the
cell/tissue of interest, leading to a finely tuned alteration in cell
fate/functional response. In light of this tight regulation, it is
perhaps unsurprising that dysregulation of PKC isoforms has
been implicated in a plethora of cancers. Alterations in PKC
isoenzyme expression have been implicated in transformation
events in a number of cell types [13]. Interestingly, the
PKCι-knockout mouse is the only model to generate an
embryonic lethal phenotype [14]. In the present paper, we
review the emerging important role of PKC isoforms in the
pathophysiology of chronic lymphocytic leukaemia (CLL).
Chronic lymphocytic leukaemia
CLL is the most common leukaemia in the Western world,
accounting for 1% of new cancer cases in the U.K. and
∼35% of all leukaemia types in adults [15]. CLL is
characterized by the accumulation of long-lived mature
monoclonal B-cells with the distinctive phenotype: CD19hi,
CD5+ , CD23+ , IgMlo, FCM7− [15]. Although CLL was
originally considered to be a malignancy of defective
apoptosis following the discovery that Bcl-2 family of anti-
apoptotic proteins were deregulated, it is now established to
be a dynamic disorder, with rates of both proliferation and
apoptosis of up to 2% of the clone size per day [16]. CLL
cell division occurswithin ‘proliferation centres’ in the lymph
nodes through interaction with the stromal niche antigen and
co-stimulation by activatedCD4+ T lymphocytes expressing
CD40 ligand (CD40L), and IL-4 attracted by Ki67+ CLL
cells [16,17]. Two major prognostic subtypes of CLL are
defined by mutational status of variable region within the
immunoglobulin heavy chain gene (IgVH) of the B-cell
receptor (BCR); mutated (M) IgVH genes are associated with
favourable outcomes, whereas cases harbouring unmutated
(UM) IgVH genes, which can also express ζ -chain (T-cell
receptor)-associated protein kinase of 70 kDa (ZAP-70) and
CD38, display more aggressive disease and more frequently
require therapeutic intervention [18,19]. UM-CLL cells
generally retain the ability to transmit signals through their
BCR in comparison with M-CLL cells [20], with sustained
BCR cross-linking resulting in a phosphoinositide 3-kinase
(PI3K)/Akt-mediated up-regulation of Mcl1, which has been
shown to increase CLL cell chemoresistance [21–23]. These
studies highlight the central role played by BCR-mediated
signalling in the pathogenesis of CLL [24]. Therefore a
deeper understanding of the signalling pathways that regulate
CLL survival and proliferation will highlight key therapeutic
targets for inhibition.
PKC isoforms in CLL
The deregulation of PKC activity/expression in CLL cells
was recognized in an early study demonstrating that total
PKC activity in CLL was lower than that observed in
acute myeloid leukaemia (AML) and acute lymphoblastic
leukaemia (ALL) in the particulate and cytosolic fractions;
however, a high level of PKCβ expression was associated
with CLL in comparison with PKCα and PKCγ [25].
These findings were supported and extended by a study
comparing PKC profiles in CLL cells [26]. In comparison
with normal mature peripheral-blood-derived B-cells, PKCα
and PKCβI expression was down-regulated in CLL cells,
whereas PKCβII and PKCε expression was up-regulated.
Indeed, PKCβII overexpression in CLL cells was indicated
to play a role in CLL pathogenesis, as PKCβII protein levels
increase with disease stage and tumour burden [26].
Initial studies assessing the role of PKC in CLL cells
utilized reagents such as the macrocyclic lactone bryostatin
and the phorbol ester PMA, which globally modulate PKC
activities and signalling pathways. In this way, elevated
PKC activity was shown to play a role in CLL cell
differentiation [27,28], enhanced CLL immunomodulation
[29] and increased cell survival and chemoresistance [30,31].
The role of PKC in these processes was inferred by the
use of PKC selective inhibitors; however, these studies did
not establish the function of individual PKC isoforms. As
the complexity of the PKC family has become apparent,
subsequent studies have utilized complementary approaches
to confirm the role of specific PKC isoforms in CLL cell
function.
PKCα
PKCα expression is down-regulated in CLL cells compared
with normal mature B-cells [26]. Interestingly, we had
previously shown that inhibiting PKCα activity in B-cell
lineage progenitors resulted in the initiation of a CLL-like
disease. This was achieved by stably expressing a plasmid-
encoding kinase dead PKCα (PKCα-KR) in a haemopoietic
stem and progenitor cell-enriched population from wild
type mice and culturing these cells in B-cell generation
systems in vitro and in vivo. The resultant cells exhibited
hallmark characteristics of human CLL cells at the level of:
(i) phenotype, e.g. CD19hi CD5+ CD23+ IgMlo; (ii) cell
cycle phase (halted in G0/G1 ex vivo); and (iii) resistance to
apoptosis [32].CLLcells generated in vivo accumulated in the
lymphoreticular system similar to that noted inCLLpatients,
demonstrating the applicability of this murine CLL model
to the human disease. Our recent work indicates that the
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Figure 1 Key events mediated by the BCR
BCR signalling regulates B-cell development and function. Coupling of the BCR with PKCβ results in up-regulated MAPK
and NF-κB signalling, leading to apoptotic resistance. In addition, PKCβ has been shown to deactivate the non-receptor
tyrosine kinase Btk, by phosphorylating Ser180 and disrupting plasma membrane targeting. The PI3K-dependent PKCδ is
activated by Syk, a tyrosine kinase proximal to the BCR. PKCδ activation is associated with elevated prosurvival signalling
such as Notch2 and stabilization of anti-apoptotic factors such as Mcl-1 and XIAP. Ag, antigen; BLNK, B-cell linker; ERK,
extracellular-signal-regulated kinase; GRB2L, Grb2 (growth-factor-receptor-bound protein 2)-like; IKK, inhibitor of NF-κB
kinase; MEK, MAPK/ERK kinase; PLC, phospholipase C.
PKCα-KR-CLL model exhibits key characteristics of poor
prognosticCLL,with cells expressingZAP-70 andpossessing
enhanced proliferative capacity both in vivo and in vitro.
Moreover, PKCβII expression is up-regulated during disease
progression, suggesting that a functional down-regulation of
PKCα signals may generate permissive conditions for the
initiation of CLL [33].
PKCβ
The BCR mediates key events during the life cycle of the
B lymphocyte to regulate B-cell development and immune
cell function. By coupling to the appropriate intracellular
signalling molecules, BCR ligation triggers proliferative,
survival, differentiation, anergic and/or apoptotic responses.
PKCβ has previously been demonstrated to play a critical
role in B-cell development, due to its ability to link the BCR
with downstream signalling pathways [12]. Indeed, PKCβ
has been demonstrated to regulate the nuclear factor κB (NF-
κB) signalling pathway downstream of BCR activation [34],
in addition to deactivating the non-receptor tyrosine kinase
Bruton tyrosine kinase (Btk), by phosphorylating Ser180
and disrupting plasma membrane targeting [35] (Figure 1).
Given the prognostic significance of the BCR in CLL
[24], it is perhaps unsurprising that PKCβ overexpression,
specifically PKCβII, is linked to poorer prognostic outcome
[26]. PKCβ is also aberrantly up-regulated in other B-
lymphocyte malignancies including diffuse large B-cell
lymphoma (DLBCL) and mantle cell lymphoma [36,37]. Of
note, CLL development in the Tcl-1 transgenic CLL mouse
model was abrogated in the absence of PKCβ, supporting a
critical role for this PKC isoform in CLL pathogenesis [38].
Assessment of expression levels demonstrated that
PKCβII is the dominant PKC isoform expressed in CLL
cells, and PKCβII is routinely present in the active
form compared with normal B-cells, with membrane-
association correlating with its activity. Supporting the role
of PKCβ in the negative regulation of Btk, the levels of
membrane-associated PKCβII are inversely related to
membrane-associated Btk.Moreover, calcium responses after
BCR ligation were lower in CLL cells that expressed
higher levels of PKCβII [26]. Collectively, these findings
demonstrate that PKCβII level/activity plays a central
role in modulating signals proximal to the BCR in CLL
cells.
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PKC- and PI3K-mediated signalling pathways have been
established to govern CLL cell survival [21,39]. PKCβ
activity can promote phosphorylation/activation of Akt,
thus promoting CLL cell survival [40]. In addition, PKCβ
regulates Akt by modulating the expression of protein
tyrosine phosphatase non-receptor type 22 (PTPN22), a
phosphatase that is responsible for positively regulating
Akt activity, which is overexpressed in CLL cells [41].
The PKCβ selective inhibitor ruboxistaurin down-regulated
PTPN22 and enhanced apoptosis downstream of BCR
ligation. Additional mechanisms supporting the pro-survival
role of PKCβII are demonstrated in a study showing that
PKCβII shuttles to the mitochondrial membrane where
it phosphorylates Bcl-2, enabling it to sequester the pro-
apoptotic protein BimEL, as well as phosphorylating BimEL
and targeting it for proteosomal degradation. These actions
skew the CLL cell fate towards apoptotic resistance [42].
Despite expressing high levels of Bcl-2, primary CLL cells
require the presence of stromal cells during in vitro culture
for long-term survival, suggesting that together with their
autonomous apoptotic defect, they rely on paracrine signals
from the tumourmicroenvironment [43,44]. PKCβII can also
be activated downstream of growth factors such as vascular
endothelial growth factor (VEGF) [45], indicating that the
activation status of PKCβII and thus its pro-survival function
is linked to the lymphoid organ microenvironment of CLL
patients. Recently, it was demonstrated that incubation of
CLL leukaemic cells with bone marrow stromal cells led
to an up-regulation in PKCβII expression and subsequent
activation ofNF-κB signalling in the stromal cells, which was
essential forCLL cell survival [44]. This study emphasizes the
complex interplay that occurs between leukaemic cells and
their stromal niche andhighlights the potential for therapeutic
intervention to disrupt both the malignancy and the tumour-
associated microenvironment.
PKCδ
PKCδ is constitutively active in freshly isolated CLL
cells. PKCδ activation, as indicated by Thr505 phosphoryla-
tion, is mediated through a PI3K-dependent pathway [46].
Inhibition of PKCδ resulted in the induction of caspase-
dependent apoptosis, and reduction in expression of the anti-
apoptotic factors Mcl-1 and X-linked inhibitor of apoptosis
(XIAP) [47], suggesting that in addition to PKCβII, PKCδ
may play a key role in regulating CLL cell survival. The
phosphorylation status of PKCδ has also been linked to
spleen tyrosine kinase (Syk), a tyrosine kinase that is proximal
to the BCR. Syk activation results in PKCδ-mediated
stabilization of Mcl-1, with inhibition of Syk leading to
a decrease in PKCδ phosphorylation and an elevation in
apoptosis [48] (Figure 1). These studies indicate that PKCδ
is associated with CLL cell survival and regulation of Mcl-
1 expression, a key antiapoptotic factor associated with
chemoresistance [22]. PKCδ is responsible for activation
of Notch2 signalling in CLL cells [49]. Increased Notch2
signalling is associated with elevated cell survival in CLL cells
[50]. However, the activated Notch2 signal is significantly
down-regulated in CLL cells after in vitro culture for 24 h,
suggesting that the PKCδ/Notch2 signalling pathway is
activated in response to microenvironmental stimuli [49].
Targeting PKCs: current and future
directions
As the PKC family has long been considered to play a major
role in the pathogenesis of a number of diseases, there has
been a focus to develop compounds that selectively modulate
the activity of individual isoforms. Therapeutic targeting of
individual PKC isoforms represents a significant challenge
because PKC isoforms share 70% homology at the ATP
binding site,making it extremely difficult to develop isoform-
specific drugs [51]. In spite of the initial promise of PKC
modulators as a treatment for human diseases, the outcome
at clinical trial has been varied and for the most part negative
[51].Most small-molecule inhibitors exhibit undesired off/on
target effects making it difficult to translate adequate drug
concentrations from animal studies to human clinical trials.
Moreover, a lack of pharmacological biomarkers to predict
drug efficacy affects the cost and success of clinical trials [51].
Indeed rotterlin, marketed as a PKCδ and Ca2+ /calmodulin-
dependent protein kinase II (CaMKIII) inhibitor, was later
shown to also inhibit protein kinases such as checkpoint
kinase 2 (CHK2), Polo-like kinase 1 (PLK1) and mitogen-
activated protein kinase (MAPK)-activated protein kinase 2
(MAPKAPK2). The cellular effects observed with rotterlin
treatment didnot correlatewith results generatedusingkinase
dead PKCδ, siRNA knockdown of PKCδ or other more
selective PKC inhibitors [52].
Early studies showing that bryostatin increased susceptib-
ility of CLL cells to induce apoptosis and/or differentiation
[27,28] prompted the clinical assessment of this PKC
modulator either alone or in combination with fludarabine
or vincristine [53,54]. Patients tolerated bryostatin well,
and the in vitro findings were supported, with CLL cells
undergoing differentiation and a reduction in PKC activity
during treatment. Bryostatin was also studied in combination
with the anti-CD20 monoclonal antibody rituximab in a
Phase II clinical trial (NCT00087425), but the study did not
produce data and is now closed. Increased clinical activity of
rituximab with conventional chemotherapeutic agents likely
made bryostatin-based therapies difficult to justify in CLL.
The first PKC inhibitors used in clinical trial were
the staurosporine-derivatives midostaurin (PKC412) and
UCN-01 (7-hydroxysporine). Midostaurin was found to
be selectively toxic towards the CLL cells compared with
peripheral blood lymphocytes in vitro [55]. In a Phase II
clinical trial, PKC412 was well tolerated by patients, and
a reduction in circulating tumour load was noted in more
than half of the patients enrolled in the trial and the majority
showed a decrease in PKC activity [56]. In addition, PKC412
enhanced cell killing induced by chlorambucil in vitro [55].
UCN-01 induced apoptosis in CLL cells both in vivo and
in vitro alone or in combination with fludarabine [57,58].
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These studies suggest that targeting PKC may provide a
valid therapeutic strategy in CLL and other haematological
malignancies.
In CLL, the BCR holds significant prognostic importance,
therefore inhibiting the signalling pathways that emanate
downstream of BCR ligation are of therapeutic relevance. In-
deed, a variety of emerging novel agents are being developed
that target BCR signalling components or downstream
effectors [59]. Given the evidence supporting a central role
for PKCβII in regulating CLL cell survival downstream
of the BCR and within tumour microenvironment, this
PKC isoform represents a very attractive therapeutic target.
Enzastaurin (LY317615), a small-molecule inhibitor targeted
towards PI3K/PKCβ pathways, has been demonstrated to
induce apoptosis in CLL cells in vitro [38,42]; however, there
is limited published data available from clinical trials in CLL
patients. Enzastaurin showed promise in Phase II clinical
trials as monotherapy in DLBCL patients [60]; however, at
Phase III in the PRELUDE trial, no clinical significance was
observed. It will be interesting to determine whether enza-
staurin may be better used as part of a combination therapy,
as it has previously been shown to enhance the apoptosis
in CLL cells in vitro upon combination with fludarabine,
vincristine, doxorubicin and bendamustine [42,61]. The use
of the PKCβ-selective inhibitor ruboxistaurin (LY333531)
in a clinical trial for treatment of leukaemia/lymphoma
has not been reported. However, although this inhibitor
induced significant apoptosis of CLL cells in response to
BCR ligation, survival was unaffected by drug treatment
in unstimulated CLL cells [40,41]. These findings indicate
that although isoform-selective inhibitors may inhibit certain
aspects of disease progression, they will not be curative,
suggesting that less-selective PKC inhibitors may hold the
key to a promising therapy.
Marked apoptosis has been noted in CLL cells treated
with RO32-0432, a pan PKC inhibitor [26]. Sotrastaurin
(AEB071), an inhibitor of conventional and novel PKC iso-
types, is currently being developed as an immunosuppressive
agent for organ transplantation. However, sotrastaurin has
been shown to have anti-tumour effects in DLBCL resulting
in cell cycle arrest and cell death both in vitro and in vivo
[62] and is currently being used in a Phase I clinical trial
for DLBCL and melanoma. Encouragingly, sotrastaurin has
recently been shown to display selective cytotoxicity towards
CLL cells and can inhibit their proliferation by altering the
BCR-dependant survival pathways (MAPK, PI3K and NF-
κB). Sotrastaurin not only reduced the levels of survival
stimuli within the CLL cells, but also disrupted signals from
the microenvironment that contribute to CLL cell survival
[63]. Although this latter effect is likely to occur through
targeting PKCβII activity, the potential success of pan PKC
inhibitors will be due to the inhibition of additional
PKC isoforms including PKCδ and PKCε.
As our knowledge of PKC biology deepens, it is evident
that specific isoenzyme inhibitors may be insufficient for
a drug to have optimal efficacy and minimal off target
effects [51]. Indeed, it may be possible to develop drugs
that inhibit the interaction of PKC with specific binding
partners. This approach requires a detailed understanding
of the molecular events that regulate PKC activation.
Although the development of separation of function
inhibiting peptides that target substrates downstream of a
single PKC isoenzyme is at an early stage, peptides have been
developed that have biological effect in disease states, holding
promise for the future [51]. Finally, early studies suggest
that a future approach towards PKC mediated therapies
may be to restore PKC activity rather than inhibiting it.
One study established that correction of a loss of function
point mutation within the regulatory domain of PKCβ in
a colon cancer cell line resulted in reduced tumour growth
in vitro and in vivo [64]. Therefore it is important to establish
whether modulation of the upstream or downstream targets
of the PKC, either inhibition or restoration of activity, would
be sufficient to change the course of the malignancy. To
achieve this, additional translational research is required: the
importance of PKC in cell fate decisions and the limitations
of current therapies justify the continued quest for PKC-
directed treatments.
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